Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

DBCOND0131146Congenital, Hereditary, and Neonatal Diseases and Abnormalities Nervous System Diseases

Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.

Also known as: Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 · CLN2 Disease · CLN2 Disorder · neuronal ceroid lipofuscinosis type 2 · Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Classified under: Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Nervous System Diseases
Nutritional and Metabolic Diseases
Indicated drugs: Cerliponase alfa

Resolves to

Vocabularies

SNOMED CT5482214014

What you can answer from here — as of October 25, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

7Clinical trialsPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account